Sotagliflozin FDA：INPEFATM (sotagliflozin) tablets
INPEFATM (sotagliflozin) tablets
See17forPATIENTCOUNSELINGINFORMATIONand.FDA-approvedMedicationGuide.Revised:05/2023.FULLPRESCRIBINGINFORMATION:CONTENTS*.1INDICATIONSANDUSAGE.。其他文章還包含有：「DualSGLT1andSGLT2inhibitorsotagliflozinachieves...」、「FDAApprovesSotagliflozinforTreatmentofHeartFailure」、「FDAApprovesSotagliflozin」、「FDAUpdate」、「Inpefa(sotagliflozin)FDAApprovalHistory」、「Inpefa(sotagliflozin)tablets」...
查看更多 離開網站
Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves ...
https://www.nature.com
The FDA has approved sotagliflozin for the reduction of major heart-failure events in patients with and or diabetes, an indication that closely ...
FDA Approves Sotagliflozin for Treatment of Heart Failure
https://www.hcplive.com
The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.
FDA Approves Sotagliflozin
https://www.ajmc.com
The FDA late Friday approved sotagliflozin, the first dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, for the treatment of ...
FDA Update
https://www.acc.org
The once-daily oral tablet is approved to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adult ...
Inpefa (sotagliflozin) FDA Approval History
https://www.drugs.com
Inpefa (sotagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of heart failure.
Inpefa (sotagliflozin) tablets
https://www.accessdata.fda.gov
for Inpefa (sotagliflozin) tablets. This NDA provides for the use of ... Form FDA 2253 is available at FDA.gov.4. Information and Instructions ...
Sotagliflozin Gets FDA Approval in HF Across EF Spectrum
https://www.tctmd.com
The US Food and Drug Administration has approved sotagliflozin for the prevention of cardiovascular death, hospitalization for heart failure (HF) ...
禮來！FDA批准糖尿病藥SGLT12雙重抑制劑治療心衰竭
https://news.gbimonthly.com
Sotagliflozin是首個用於治療第1型和第2型糖尿病的SGLT2與SGLT1雙重抑制劑。該藥是由Lexicon與賽諾菲(Sanofi)共同合作開發，但在2019年，由於多項臨床試驗 ...